Results of GBV-C/HGV RNA and Anti-E2 Determination Observed at the Baseline and at the End of the Six-Year Follow-up Period in 150 Homozygous β-Thalassemic Patients
| At Baseline (1989-1990) . | End of Follow-up (1995-1996) . | ||||
|---|---|---|---|---|---|
| GBV-C/HGV RNA . | Anti-E2 . | No. of Subjects . | GBV-C/HGV RNA . | Anti-E2 . | No. of Subjects . |
| neg | neg | 100* | neg | neg | 90 |
| pos | neg | 2 | |||
| neg | pos | 7 | |||
| pos | pos | 1 | |||
| pos | neg | 22 | pos | neg | 14 |
| neg | neg | 2 | |||
| neg | pos | 4 | |||
| pos | pos | 2 | |||
| neg | pos | 28 | neg | pos | 16 |
| neg | neg | 12 | |||
| At Baseline (1989-1990) . | End of Follow-up (1995-1996) . | ||||
|---|---|---|---|---|---|
| GBV-C/HGV RNA . | Anti-E2 . | No. of Subjects . | GBV-C/HGV RNA . | Anti-E2 . | No. of Subjects . |
| neg | neg | 100* | neg | neg | 90 |
| pos | neg | 2 | |||
| neg | pos | 7 | |||
| pos | pos | 1 | |||
| pos | neg | 22 | pos | neg | 14 |
| neg | neg | 2 | |||
| neg | pos | 4 | |||
| pos | pos | 2 | |||
| neg | pos | 28 | neg | pos | 16 |
| neg | neg | 12 | |||
*Including 5 patients testing GBV-C/HGV RNA− using primers from NS5a region, and GBV-C/HGV RNA+ with those from 5′-NCR. They were all negative with both primer pairs in the sample collected at the end of follow-up (1995-1996). Anti-E2 determination was persistently negative.